InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
3.000
+0.020 (0.67%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.

The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.

The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD, Inc.
InspireMD logo
Country Israel
Founded 2005
Industry Medical Devices
Sector Healthcare
Employees 66
CEO Marvin Slosman

Contact Details

Address:
4 Menorat Hamaor Street
Tel Aviv, 6744832
Israel
Phone 972 3 6917691
Website inspiremd.com

Stock Details

Ticker Symbol NSPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001433607
CUSIP Number 45779A853
ISIN Number US45779A8466
Employer ID 26-2123838
SIC Code 3841

Key Executives

Name Position
Marvin L. Slosman President, Chief Executive Officer and Director
Craig Shore Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer
Shane Thomas Gleason Chief Commercial Officer
Andrea Tommasoli Chief Operating Officer
Amir Kohen Senior Vice President of Finance and Human Resources
Dr. Patrick A. Verta DVM, M.D., MS Stat Executive Vice President of Clinical and Medical Affairs
Pete J. Ligotti Executive Vice President and GM of North America
Dr. Sol J. Barer Ph.D. Special Advisor to the Board

Latest SEC Filings

Date Type Title
Dec 12, 2024 8-K Current Report
Dec 9, 2024 8-K Current Report
Dec 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 25, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 12, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Oct 28, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 8-K Current Report